Naltrexone for the Treatment of Darier and Hailey-Hailey Diseases (Abstract)

The LDN Conference 2021: 4th - 6th June 2021

Up to 29 CME Credits Available + Sponsor, Exhibitor and Advertiser Opportunities.  [More Details]

Naltrexone for the Treatment of Darier and Hailey-Hailey Diseases

J Cutan Med Surg
24 July 2019
https://www.researchgate.net/publication/334649366_Naltrexone_for_the_Treatment_of_Darier_and_Hailey-Hailey_Diseases

The use of LDn at 4.5mg once daily in patients with HHD shows promise, doesn't require laboratory monitoring as classic doses of 50-100mg, and has a favourable safey profile with common side effects of vivid dreams and headache. Prior to LDN therapy, patients should be carefully screened for recent use and/or prior dependence of opioids. Further studies to assess the efficacy of naltredone in low-dose or higher doeses in these 2 diseases are needed.

Keywords Darier disease (DD), Hailey-Hailey disease (HHD), low-dose naltrexone (LDN), naltrexone